110 filings
8-K
HRMY
Harmony Biosciences Holdings Inc
3 May 24
Departure of Directors or Certain Officers
8:00am
10-Q
2024 Q1
HRMY
Harmony Biosciences Holdings Inc
Quarterly report
30 Apr 24
8:00am
8-K
HRMY
Harmony Biosciences Holdings Inc
30 Apr 24
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year
7:45am
ARS
2023 FY
HRMY
Harmony Biosciences Holdings Inc
11 Apr 24
Annual report to shareholders
9:44am
8-K
HRMY
Harmony Biosciences Holdings Inc
11 Apr 24
Entry into a Material Definitive Agreement
8:30am
DEFA14A
jq81qlxxcv 2ij7
11 Apr 24
Additional proxy soliciting materials
8:18am
S-8
802rokhnhr96 we
22 Feb 24
Registration of securities for employees
4:14pm
8-K
u98q7f ra
22 Feb 24
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
7:45am
8-K
lvv2 kuvvl
8 Jan 24
Results of Operations and Financial Condition
8:30am
8-K/A
i2od8 5uvjjt55y
7 Dec 23
Consolidated Financial Statements
4:06pm
8-K
n685jc8suhyihc
8 Nov 23
Harmony Biosciences Appoints
8:30am
8-K
bzokx 6tjk
31 Oct 23
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
7:45am
8-K
1kw5jq50 u6
13 Oct 23
Harmony Biosciences Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant In Patients with Idiopathic Hypersomnia
8:15am
SC TO-T/A
gnj11eoe
11 Oct 23
Third party tender offer statement (amended)
8:31am
8-K
amp44s6 h2f0ard
11 Oct 23
Harmony Biosciences Completes Acquisition of Zynerba
8:15am
8-K
irw7a9iyn6nxnl
5 Oct 23
Departure of Directors or Certain Officers
4:15pm